Peters et al. report the results of the phase 3 CheckMate 73L trial, randomizing participants with untreated, unresectable stage III non-small cell lung cancer to nivolumab plus concurrent chemoradiotherapy (CCRT) followed by consolidation with nivolumab plus ipilimumab or nivolumab alone or to standard-of-care CCRT followed by consolidation with durvalumab.
- Solange Peters
- Daniel S. W. Tan
- Dirk De Ruysscher
